Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.30.4899PMID 21860000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events

  2009cited by this paper
• Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

  2009cited by this paper
• Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.

  2008cited by this paper
• Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.

  2007cited by this paper
• Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation

  2006cited by this paper
• Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

  2005cited by this paper
• Hypoxia and anemia: effects on tumor biology and treatment resistance.

  2005cited by this paper
• Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies

  2004cited by this paper
• A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

  2004cited by this paper
• Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer

  2004cited by this paper
• Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

  2003cited by this paper
• Role of Red Blood Cells in Pharmacokinetics of Chemotherapeutic Agents

  2003cited by this paper
• Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.

  2001cited by this paper
• Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

  1999cited by this paper
• Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

  1999cited by this paper
• Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

  1999cited by this paper
• Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

  1999cited by this paper
• Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

  1999cited by this paper
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper
• Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

  1993cited by this paper

• Erythropoietin promotes cell proliferation in Neuro-2A mouse neuroblastoma cells

  2025cites this paper
• Hematologic Toxicity Profiles and the Impact of Hemoglobin Nadir and Transfusion on Oncologic Outcome in Definitive Radiochemotherapy for Cervical Cancer

  2024cites this paper
• Hemoglobin level and survival in cervical cancer with chemoradiotherapy at high altitude, 2020–2022

  2024cites this paper
• Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

  2023cites this paper
• Insights into ovarian cancer: chemo-diversity, dose depended toxicities and survival responses

  2023cites this paper
• Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study

  2022cites this paper
• Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.

  2022cites this paper
• Prognostic Significance of Lab Data and Performance Comparison by Validating Survival Prediction Models for Patients with Spinal Metastases After Radiotherapy.

  2022cites this paper
• Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials

  2021cites this paper
• PATHOGENETIC CORRECTION OF ANEMIA WITH COMBINATION THERAPY IN PATIENTS WITH COVID-19

  2021cites this paper
• The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018

  2021cites this paper
• Erythropoietin-Induced Autophagy Protects Against Spinal Cord Injury and Improves Neurological Function via the Extracellular-Regulated Protein Kinase Signaling Pathway

  2020cites this paper
• Hämatologische Toxizität der Strahlentherapie und Management

  2020cites this paper
• Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy

  2020cites this paper
• Analysis of Clinical Factors Affecting Radical Radiotherapy for Cervical Cancer

  2019cites this paper
• Роль эритропоэтинов в лечении онкологических больных

  2018cites this paper
• Niedokrwistość u chorych na nowotwory — zalecenia grupy ekspertów. Aktualizacja 2020 r.

  2018cites this paper
• Indications for and complications of transfusion and the management of gynecologic malignancies.

  2017influential citation
• Référentiels inter régionaux en Soins Oncologiques de Support

  2017cites this paper
• Anaemia in cancer patients — Expert Group recommendations

  2017cites this paper
• A Systematic review on the erythropoietin receptors expression in various cancers and importance of recombinant erythropoietin in chemotherapy induced anaemia

  2017cites this paper
• Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case–control study

  2016cites this paper
• Emerging targets for radioprotection and radiosensitization in radiotherapy

  2016cites this paper
• Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?

  2016cites this paper
• The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.

  2016cites this paper
• Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.

  2016cites this paper
• Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?

  2015cites this paper
• Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors.

  2015cites this paper
• Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients

  2014cites this paper
• Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

  2014cites this paper
• Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.

  2014cites this paper
• A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions

  2014cites this paper
• Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

  2014cites this paper
• Pharmacovigilance in practice: erythropoiesis-stimulating agents

  2014cites this paper
• Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

  2013cites this paper
• The Impact of Perioperative Packed Red Blood Cell Transfusion on Survival in Epithelial Ovarian Cancer

  2013cites this paper
• Bone Marrow Toxicity: Red Blood Cells

  2013cites this paper
• Risk of venous thromboembolism with the erythropoiesisstimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials

  2013cites this paper
• Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis

  2013cites this paper
• Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment.

  2013cites this paper
• Tissue biomarkers as prognostic variables of cervical cancer.

  2013cites this paper
• Zervixkarzinom

  2013cites this paper
• Challenges of anemia correction during radiotherapy and chemoradiation

  2012cites this paper
• Markers of treatment response for gastro-oesophageal cancers

  2012cites this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2012cites this paper
• Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy

  2012cites this paper
• Systemische Therapie in einem kurativen multimodalen Konzept

  2012cites this paper
• Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.

  2012cites this paper
• Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

  2012cites this paper